Ligand validation:6FYU

NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose

NAG is a Ligand Of Interest in 6FYU designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
6FYU_NAG_B_500	28%	78%	0.139	0.791	0.38	0.52	-	-	0	0	100%	0.9333
6FYU_NAG_E_202	19%	88%	0.132	0.723	0.31	0.36	-	-	0	0	100%	0.9333
6FYU_NAG_H_500	19%	78%	0.159	0.749	0.4	0.49	-	-	0	0	100%	0.9333
6FYU_NAG_G_402	13%	89%	0.146	0.683	0.26	0.38	-	-	0	0	100%	0.9333
6FYU_NAG_B_501	12%	88%	0.165	0.694	0.23	0.42	-	-	0	0	100%	0.9333
6FYU_NAG_H_501	10%	85%	0.145	0.652	0.27	0.46	-	-	0	0	100%	0.9333
6FYU_NAG_D_500	9%	65%	0.169	0.655	0.49	0.86	-	1	0	0	100%	0.9333
6FYU_NAG_E_201	9%	79%	0.165	0.649	0.34	0.52	-	-	0	0	100%	0.9333
6FYU_NAG_G_401	8%	79%	0.17	0.645	0.34	0.51	-	-	0	0	100%	0.9333
4LN3_NAG_K_800	100%	41%	0.04	0.989	0.44	1.83	-	3	0	0	100%	0.9333
4DJ6_NAG_C_401	99%	47%	0.054	0.984	0.51	1.5	-	3	0	0	100%	0.9333
4LN8_NAG_F_500	98%	17%	0.056	0.975	1	2.58	1	7	1	0	100%	0.9333
4DJ7_NAG_D_201	97%	46%	0.059	0.974	0.53	1.52	-	1	2	0	100%	0.9333
4LKJ_NAG_B_501	77%	68%	0.112	0.951	0.51	0.73	-	-	1	0	100%	0.9333
3H0C_NAG_A_794	100%	56%	0.021	0.995	0.61	1.08	-	1	0	0	100%	0.9333
5LDS_NAG_B_1007	100%	67%	0.022	0.995	0.48	0.79	-	-	0	0	100%	0.9333
5O5D_NAG_A_601	100%	65%	0.022	0.994	0.32	0.99	-	1	0	0	100%	0.9333
6MUG_NAG_G_629	100%	76%	0.022	0.994	0.35	0.58	-	-	0	0	100%	0.9333
3GXM_NAG_A_498	100%	45%	0.026	0.992	0.75	1.34	-	2	0	0	100%	0.9333

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.